[go: up one dir, main page]

AR053651A1 - COMBINED TREATMENT OF ANTIBODY ANTICTLA4 R AROMATASE INHIBITOR FOR BREAST CANCER - Google Patents

COMBINED TREATMENT OF ANTIBODY ANTICTLA4 R AROMATASE INHIBITOR FOR BREAST CANCER

Info

Publication number
AR053651A1
AR053651A1 ARP050104588A ARP050104588A AR053651A1 AR 053651 A1 AR053651 A1 AR 053651A1 AR P050104588 A ARP050104588 A AR P050104588A AR P050104588 A ARP050104588 A AR P050104588A AR 053651 A1 AR053651 A1 AR 053651A1
Authority
AR
Argentina
Prior art keywords
antibody
breast cancer
aromatase inhibitor
ctla4
antictla4
Prior art date
Application number
ARP050104588A
Other languages
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR053651A1 publication Critical patent/AR053651A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Administracion de un anticuerpo anti-CTLA4, particularmente anticuerpos humanos contra CTLA4 humano, tal como los que tienen secuencias de aminoácidos de los anticuerpos 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1 y 10D1 (MDX-010), en combinacion con un inhibidor de aromatasa, para el tratamiento del cáncer de mama. Más particularmente, se refiere a la administracion de un anticuerpo anti-CTLA4 y exemestano para el tratamiento del cáncer de mama, composicion farmacéutica y el uso de un anticuerpo anti-CTLA4. Reivindicacion 16: Una composicion farmacéutica para el tratamiento del cáncer de mama, que comprende: una cantidad terapéuticamente eficaz de un anticuerpo anti-CTLA4; una cantidad terapéuticamente eficaz de un inhibidor de aromatasa; y un vehículo farmacéuticamente aceptable.Administration of an anti-CTLA4 antibody, particularly human antibodies against human CTLA4, such as those having amino acid sequences of the antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1 and 10D1 (MDX-010), in combination with an aromatase inhibitor, for the treatment of breast cancer. More particularly, it refers to the administration of an anti-CTLA4 and exemestane antibody for the treatment of breast cancer, pharmaceutical composition and the use of an anti-CTLA4 antibody. Claim 16: A pharmaceutical composition for the treatment of breast cancer, comprising: a therapeutically effective amount of an anti-CTLA4 antibody; a therapeutically effective amount of an aromatase inhibitor; and a pharmaceutically acceptable vehicle.

ARP050104588A 2004-11-04 2005-11-02 COMBINED TREATMENT OF ANTIBODY ANTICTLA4 R AROMATASE INHIBITOR FOR BREAST CANCER AR053651A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62485604P 2004-11-04 2004-11-04

Publications (1)

Publication Number Publication Date
AR053651A1 true AR053651A1 (en) 2007-05-16

Family

ID=35825412

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104588A AR053651A1 (en) 2004-11-04 2005-11-02 COMBINED TREATMENT OF ANTIBODY ANTICTLA4 R AROMATASE INHIBITOR FOR BREAST CANCER

Country Status (15)

Country Link
EP (1) EP1819735A1 (en)
JP (1) JP2008518902A (en)
KR (1) KR20070067702A (en)
CN (1) CN101052655A (en)
AR (1) AR053651A1 (en)
AU (1) AU2005300315A1 (en)
BR (1) BRPI0515735A2 (en)
CA (1) CA2586844A1 (en)
IL (1) IL182244A0 (en)
MX (1) MX2007003804A (en)
NO (1) NO20072576L (en)
RU (1) RU2007114111A (en)
TW (1) TW200621804A (en)
WO (1) WO2006048749A1 (en)
ZA (1) ZA200702577B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114702A2 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CN101268101A (en) * 2005-07-07 2008-09-17 科利制药集团公司 Combination therapy of anti-CTLA-4 antibody and synthetic oligodeoxynucleotide containing CpG motif for cancer treatment
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP2007423A2 (en) * 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
US8449886B2 (en) 2008-01-08 2013-05-28 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
WO2011011027A1 (en) * 2009-07-20 2011-01-27 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
WO2010045002A2 (en) 2008-09-26 2010-04-22 Tocagen Inc. Gene therapy vectors and cytosine deaminases
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
AU2009298131B2 (en) 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
MX360254B (en) 2011-03-10 2018-10-26 Pfizer Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer.
RU2605289C2 (en) 2011-08-30 2016-12-20 Астекс Фармасьютикалз, Инк. Formulation, kit and a pharmaceutical composition containing decitabine derivatives, production and use thereof
ES3023516T3 (en) * 2011-10-14 2025-06-02 Hoffmann La Roche Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
SG10201603896RA (en) 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
CN103768596B (en) * 2012-10-17 2016-06-22 苏州丁孚靶点生物技术有限公司 For the combination product of oncotherapy, its purposes and correlation technique
EP3623478A1 (en) 2012-10-25 2020-03-18 Tocagen Inc. Retroviral vector with mini-promoter cassette
CA2902433A1 (en) 2013-03-01 2014-09-04 Astex Pharmaceuticals, Inc. Drug combinations
CA2926853C (en) * 2013-10-18 2022-04-26 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
CN108024535A (en) 2015-07-02 2018-05-11 大塚制药株式会社 Freeze-drying medicinal composition
EA201890640A1 (en) 2015-09-04 2018-09-28 Токаджен Инк. RECOMBINANT VECTORS CONTAINING PEPTIDE 2A
CN106883298B (en) 2015-12-16 2021-12-17 上海康岱生物医药技术股份有限公司 Bispecific conjugated antibodies, methods of making and uses thereof
DK3400293T4 (en) 2016-01-08 2023-08-28 Replimune Ltd Modified oncolytic virus
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
BR112018076281A2 (en) 2016-06-20 2019-03-26 Kymab Limited immunocytocin, use of an immunocytocin, method, pharmaceutical composition, method for treating a proliferative disease in an animal, nucleic acid, vector, host and antibody or fragment thereof
JP7198666B2 (en) * 2016-08-26 2023-01-04 哲治 奥野 Microvascular blood flow reducing agent and its use
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
KR20190096384A (en) 2017-03-02 2019-08-19 제넨테크, 인크. HER2-positive breast cancer adjuvant treatment
WO2018167780A1 (en) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
CN111182908A (en) 2017-08-03 2020-05-19 大塚制药株式会社 Pharmaceutical compounds and methods for their purification
EP4110347A4 (en) * 2020-02-27 2024-05-29 University of Washington Composition and method to prepare long-acting injectable suspension containing multiple cancer drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies

Also Published As

Publication number Publication date
JP2008518902A (en) 2008-06-05
MX2007003804A (en) 2007-04-23
TW200621804A (en) 2006-07-01
AU2005300315A1 (en) 2006-05-11
KR20070067702A (en) 2007-06-28
WO2006048749A1 (en) 2006-05-11
NO20072576L (en) 2007-08-03
CA2586844A1 (en) 2006-05-11
EP1819735A1 (en) 2007-08-22
BRPI0515735A2 (en) 2011-10-11
CN101052655A (en) 2007-10-10
ZA200702577B (en) 2008-07-30
IL182244A0 (en) 2007-09-20
RU2007114111A (en) 2008-12-10

Similar Documents

Publication Publication Date Title
AR053651A1 (en) COMBINED TREATMENT OF ANTIBODY ANTICTLA4 R AROMATASE INHIBITOR FOR BREAST CANCER
AR060306A1 (en) ANTIBODY COMBINATION THERAPY AGAINST CTLA4
AR109461A2 (en) FORMULATION OF ANTI-CD20 ANTIBODY AND ITS USE TO PREPARE A MEDICINAL PRODUCT
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
MX347525B (en) Inhibitors of bruton's tyrosine kinase.
ECSP088974A (en) IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHEOSE QUINASA GLYCOGEN (GSK3)
CO6331425A2 (en) COMPOSITIONS THAT INCLUDE N- (3,4-DIFLUORO-2- (2-FLUORO-4-IODOFENILAMINO) 6-METOXIFENIL) -1- (2,3-DIHYDROXIPROXIPROPIL) CICLOPROPAN-1-SULFAMIDA
AR090349A1 (en) COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS, KIT AND USE
CY1110013T1 (en) Combinations For Multiple Myeloma Therapy
AR072442A1 (en) METHOD FOR CANCER THERAPY, USE, KIT
CU23821A3 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A DIFFENILUREA REPLACED WITH OMEGA-CARBOXIARIL FOR THE TREATMENT OF CANCER
CO6300964A2 (en) A PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMBINATION OF A CHEMOTHERAPEUTIC AGENT AND AN ANTIGLIPICAN ANTIBODY 3
WO2008091620A3 (en) Combination therapy comprising romidepsin and i.a. bortezomib
MX353964B (en) THERAPEUTIC AGENTS AND USES OF THE SAME.
CL2008001297A1 (en) N - [(1s) -1- (5-fluoropyrim idin-2-i1) ethyl] -3- (5-isopropoxy-1 h-pyrazol-3-yl) -3h-imidazo [4,5-b] pyridine -5amine or a pharmaceutically acceptable salt thereof; pharmaceutical composition comprising it; and its use in the treatment of cancer.
BRPI0516531A (en) autoimmune disorders immunotherapy
UY30158A1 (en) USE OF BENZO-HETEROARIL SULFAMIDA DERIVATIVES FOR PAIN TREATMENT
CY1109537T1 (en) Peptides and Peptide Derivatives, PREPARATION OF THESE ALSO USE THESE FOR THE PREPARATION OF THERAPEUTIC AND / OR PREVENTIVE ACTIVE ACTION
DOP2009000208A (en) METHODS OF TREATMENT OF CANCER THROUGH ADMINISTRATION OF HUMAN IL-18 COMBINATIONS
CL2008002082A1 (en) Compounds derived from 6-phenyl-1h-imidazo [4,5-c] pyridine-4-carbonitrile, inhibitors of cathepsin s and cathepsin k; pharmaceutical composition; and use in the treatment of osteoporosis, atherosclerosis, inflammation, among other diseases.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
MX2009011900A (en) Diabetic wound healing.
CL2008002466A1 (en) Anhydrous topical pharmaceutical composition comprising a vasodilator and an acceptable carrier; use of topical anhydrous composition on genital areas for improved sexual well-being.
ECSP066878A (en) [HYDROCHLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL] - (4-BROMO-3-METHYL-5-PROPOXI-THIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE TRIPTASE
WO2010048365A3 (en) Therapeutic peptide bioconjugates

Legal Events

Date Code Title Description
FA Abandonment or withdrawal